<DOC>
	<DOCNO>NCT00373542</DOCNO>
	<brief_summary>The purpose study assess efficacy safety ropinirole CR-RLS treatment patient Restless Legs Syndrome associate sleep disturbance period limb movement sleep .</brief_summary>
	<brief_title>12-week Polysomnography Study Ropinirole Controlled Release Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<criteria>Inclusion criterion : provide write informed consent . Diagnosed primary RLS use International RLS Study Group Diagnostic Criteria total score 20 great International RLS ( IRLS ) Rating Scale significant sleep disturbance indicate Item 4 IRLS rating scale . Have even nighttime symptom RLS , significant sleep impairment due RLS symptom , symptom require treatment prior bedtime , early 5:00PM . Sleep efficiency &lt; 85 % OR Latency persistent sleep &gt; 20 minute . Exclusion criterion : Secondary RLS Primary sleep disorder Have medical condition may impact efficacy assessment may present safety concern . Pregnant lactate woman childbearing potential practicing acceptable method birth control . Use prohibit medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Restless Legs Syndrome</keyword>
	<keyword>ropinirole</keyword>
	<keyword>polysomnography</keyword>
	<keyword>RLS</keyword>
	<keyword>PSG</keyword>
</DOC>